SCHEMBL6911987

SCHEMBL6911987

CNCC1COC(c2nc(-c3ccncc3)c(-c3ccc(F)cc3)[nH]2)OC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 13/20 0.54
MAPK12 P53778 13/20 0.54
MAPK11 Q15759 13/20 0.54
MAPK14 Q16539 13/20 0.54
CSNK1A1 P48729 2/20 0.54
CSNK1D P48730 2/20 0.54
RPS6KA3 P51812 1/20 0.54
MAPK9 P45984 4/20 0.54
RAF1 P04049 3/20 0.54
GCGR P47871 5/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
FRK P42685 1/20 0.47
GSK3B P49841 1/20 0.47
PTK6 Q13882 1/20 0.47
PRKD2 Q9BZL6 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
BRAF P15056 1/20 0.46
ALOX5 P09917 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5771436 0.85 CSNK1D (0.67) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5771859 0.82 MAPK14 (0.56) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL6911991 0.82 CSNK1A1 (0.57) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL27518737 0.80 CSNK1A1 (0.61) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5769549 0.80 MAPK13 (0.66) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5770995 0.79 SOAT1 (0.68) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5770420 0.79 MAPK14 (0.58) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL6075437 0.79 CSNK1A1 (0.59) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5797741 0.79 SOAT1 (0.70) MAPK13MAPK12MAPK11MAPK14CSNK1A1
SCHEMBL5769354 0.78 MAPK13 (0.60) MAPK13MAPK12MAPK11MAPK14CSNK1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040038991-A1 Imidazolyl-cyclic acetals AVENTIS PHARMA LIMITED (GB) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038991-A1 Imidazolyl-cyclic acetals CBR1, LBR, CBR3 MAPK13 1610/4885MAPK12 2766/4885MAPK11 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.